Plain-English translation of NCT06902896 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called FAP-targeted immunosuppressive chimeric antigen receptor-dendritic cell (iCDC) therapy for people with end-stage dilated cardiomyopathy—a serious condition where the heart becomes enlarged and cannot pump blood effectively. The treatment involves collecting some of your immune cells, modifying them in a laboratory to target problematic cells in the heart, and then infusing them back into your body. Researchers hope this medication may help reduce scarring, improve heart function, and improve symptoms.
People with end-stage dilated cardiomyopathy often have limited treatment options and face serious complications, including the need for a heart transplant. This trial is testing whether this new immune cell therapy could offer a new way to slow disease progression and improve quality of life for patients with this condition.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will undergo a procedure called leukapheresis, in which some of your blood is removed to collect immune cells. These cells will be sent to a laboratory where they are modified and grown. In Phase 1, the research team will test different doses of the modified cells to find the safest and most effective dose; in Phase 2, participants will receive the dose that worked best. You will receive one or more infusions of these cells and will be monitored closely with heart imaging tests, blood work, walking tests, and symptom assessments. The trial also includes a control group—some people will choose to continue standard heart failure care without receiving the cell therapy and will be followed alongside the treatment group for comparison.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Enrollment target
~43 participants
Started
April 2025
Primary completion
June 2028
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jiamin Li, MD
2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.